Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
68
BLTE Quote, Financials, Valuation and Earnings
Last price:
$149.55
Seasonality move
:
0.88%
Day range:
$140.07 - $151.79
52-week range:
$49.00 - $160.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
20.53x
Volume:
314.5K
Avg. volume:
202.6K
1-year change:
130.72%
Market cap:
$5.6B
Revenue:
--
EPS (TTM):
-$1.92
Analysts' Opinion
-
Consensus RatingBelite Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $184.33, Belite Bio, Inc. has an estimated upside of 22.89% from its current price of $150.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $140.00 representing 6.67% downside risk from its current price of $150.00.
Fair Value
-
According to the consensus of 5 analysts, Belite Bio, Inc. has 22.89% upside to fair value with a price target of $184.33 per share.
BLTE vs. S&P 500
-
Over the past 5 trading days, Belite Bio, Inc. has overperformed the S&P 500 by 8.8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Belite Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Belite Bio, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Belite Bio, Inc. reported revenues of --.
Earnings Growth
-
Belite Bio, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Belite Bio, Inc. reported earnings per share of -$0.65.
Enterprise value:
5.4B
EV / Invested capital:
19.49x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-1.07x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$347K
Return On Assets:
-35.82%
Net Income Margin (TTM):
--
Return On Equity:
-37.13%
Return On Invested Capital:
-37.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -$347K | -- | -$347K | |
| Operating Income | -$31.4M | -$35.5M | -$67.6M | -$9.7M | -$23M | |
| EBITDA | -$31.2M | -$35.5M | -$67.2M | -$9.7M | -$22.7M | |
| Diluted EPS | -$0.99 | -$1.11 | -$1.92 | -$0.28 | -$0.65 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $56.1M | $111.3M | $277.2M | |
| Total Assets | -- | -- | $57.6M | $115.8M | $282.4M | |
| Current Liabilities | -- | -- | -- | -- | $8.1M | |
| Total Liabilities | -- | -- | $4.8M | $3.6M | $8.3M | |
| Total Equity | -- | -- | $52.8M | $112.2M | $274.1M | |
| Total Debt | -- | -- | -- | -- | $245K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-07 | 2024-12-07 | 2024-12-07 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BLTE
Sector
Market Cap
$5.6B
$28.5M
Price % of 52-Week High
93.43%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0%
-1.33%
1-Year Price Total Return
130.72%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$144.10
200-day SMA
Buy
Level
$73.42
Bollinger Bands (100)
Buy
Level
59.63 - 110.59
Chaikin Money Flow
Buy
Level
9.1M
20-day SMA
Buy
Level
$127.76
Relative Strength Index (RSI14)
Buy
Level
70.16
ADX Line
Buy
Level
40.82
Williams %R
Sell
Level
-19.2976
50-day SMA
Buy
Level
$103.94
MACD (12, 26)
Buy
Level
13.76
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
19.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (190.1829)
Buy
CA Score
(Annual)
Level (0.1727)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (8.3196)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, BLTE has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLTE average analyst price target in the past 3 months is $184.33.
-
Where Will Belite Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Belite Bio, Inc. share price will rise to $184.33 per share over the next 12 months.
-
What Do Analysts Say About Belite Bio, Inc.?
Analysts are divided on their view about Belite Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Belite Bio, Inc. is a Sell and believe this share price will drop from its current level to $140.00.
-
What Is Belite Bio, Inc.'s Price Target?
The price target for Belite Bio, Inc. over the next 1-year time period is forecast to be $184.33 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BLTE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Belite Bio, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BLTE?
You can purchase shares of Belite Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Belite Bio, Inc. shares.
-
What Is The Belite Bio, Inc. Share Price Today?
Belite Bio, Inc. was last trading at $149.55 per share. This represents the most recent stock quote for Belite Bio, Inc.. Yesterday, Belite Bio, Inc. closed at $150.00 per share.
-
How To Buy Belite Bio, Inc. Stock Online?
In order to purchase Belite Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BLTE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BLTE
Sector
P/E ratio
--
23.75x
PEG ratio
-1.07x
-0.01x
P/B ratio
20.53x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
BLTE
Sector
Revenue growth
--
4.85%
Earnings growth
-130.87%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.49
-$0.20
Profitability
BLTE
Sector
Profitability FY 2024
-$449K
$3.6M
Return on invested capital
-37.09%
-30.98%
Return on assets
-35.82%
-27.62%
Return on equity
-37.13%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
9
Balance Sheet
BLTE
Sector
Total cash
$275.6M
$27.2M
Short term investments
$113.5M
$25.7M
Total assets
$152.1M
$79.7M
Long term debt
$245K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
